Zyprexa vs. Latuda

See how Zyprexa and Latuda compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Both drugs treat schizophrenia, but only Zyprexa is approved for acute mania and agitation, while only Latuda is approved for bipolar depression as its own standalone treatment.

  • Zyprexa causes substantially more weight gain and metabolic change than Latuda based on head-to-head trial data, which matters most for patients with metabolic risk factors.

  • Zyprexa comes in more forms, including a long-acting monthly injection, while Latuda is oral-only and must be taken with a substantial meal to absorb properly.

Zyprexa vs. Latuda Drug Summary

Zyprexa

Zyprexa (olanzapine) is an atypical antipsychotic used for schizophrenia and bipolar I disorder, covering mania, long-term maintenance, and acute agitation. It comes as a tablet, an orally disintegrating tablet, a short-acting injection, or a long-acting monthly injection (Relprevv). Combined with fluoxetine, it is also used for certain bipolar and treatment-resistant depression.

Latuda

Latuda (lurasidone) is an atypical antipsychotic used for schizophrenia and for depressive episodes tied to bipolar I disorder, alone or added to lithium or valproate. It is taken once daily by mouth with a substantial meal, usually without any initial dose titration. It is not approved for the manic phase of bipolar disorder.

Zyprexa vs. Latuda Side Effects

Zyprexa

Most common
Somnolence (up to 52%)
Akathisia (up to 27%)
Dizziness (up to 18%)
Weight gain (up to 10%)

Latuda

Most common
Somnolence (up to 12%)
Akathisia (up to 15%)
Extrapyramidal symptoms (up to 15%)
Nausea (up to 10%)

Zyprexa vs. Latuda Dosage

Zyprexa

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 5-10 mg once daily At the start
Maximum dose 2.5-10 mg per IM dose If needed
Dose changes 4 increases As tolerated

Latuda

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 40 mg once daily At the start
Maximum dose 40-80 mg once daily If needed
Dose changes 4 increases As tolerated

Zyprexa vs. Latuda Indications

Zyprexa

Zyprexa is FDA-approved for schizophrenia and for bipolar I disorder, covering acute mania, long-term maintenance, and short-acting injections for agitation. Combined with fluoxetine, it is also approved for bipolar and treatment-resistant depression. It is not approved for dementia-related psychosis in older adults.

  • Schizophrenia in adults and adolescents (13-17)

  • Bipolar I mania, alone or with lithium or valproate

  • Long-term maintenance of bipolar I disorder

  • Acute agitation from schizophrenia or bipolar mania

Latuda

Latuda is FDA-approved for schizophrenia and for major depressive episodes tied to bipolar I disorder, alone or added to lithium or valproate. It is not approved for the manic phase of bipolar disorder or for acute agitation. Like Zyprexa, it carries a boxed warning against use in older adults with dementia-related psychosis.

  • Schizophrenia in adults and adolescents (13-17)

  • Bipolar I depression monotherapy in adults

  • Bipolar I depression monotherapy in ages 10-17

  • Bipolar I depression with lithium or valproate (adults)

Zyprexa vs. Latuda Pros and Cons

Zyprexa

Zyprexa has the broadest bipolar indication of the two, covering mania, maintenance, and acute agitation, along with a long-acting monthly injection option. It has been on the market since 1996 with an established generic, but its metabolic side effect profile is more pronounced than Latuda's.

Pros

  • Approved for acute mania and short-term agitation, not just depression

  • Available as a long-acting monthly injection (Relprevv) for maintenance

  • Long real-world track record, on the market since 1996

  • Typically costs less out-of-pocket, roughly $440 to $900 per month without insurance, before savings programs

Cons

  • Causes substantially more weight gain and metabolic change than Latuda in trial data

  • Not approved for bipolar depression on its own, only combined with fluoxetine

  • Long-acting injection requires a 3-hour monitored observation after each dose

  • Somnolence is very common, reported in roughly half of patients in trials

Latuda

Latuda's main clinical edge is a lower burden of weight gain and metabolic change, backed by head-to-head trial data against olanzapine. It only covers schizophrenia and bipolar depression, so it cannot replace Zyprexa for mania or acute agitation.

Pros

  • Causes far less weight gain and metabolic change than olanzapine in trial data

  • No initial dose titration needed for most patients to reach an effective dose

  • Approved for bipolar depression on its own, including ages 10 and up

  • Linked to smaller changes in blood sugar and cholesterol than olanzapine in trials

Cons

  • Not approved for acute mania or agitation, unlike Zyprexa

  • No injectable form exists for patients who cannot take oral medication

  • Must be taken with a substantial meal (at least 350 calories) to absorb well

  • Costs significantly more than Zyprexa, roughly $1,100 to $1,900 per month without insurance, before savings programs

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.